- Home
- NTRB vs NSRX Comparison
NTRB vs NSRX Comparison
Compare NTRB & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | NSRX |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | Israel |
| Employees | 3 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 53.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NTRB | NSRX |
|---|---|---|
| Price | $4.00 | $4.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 10.6K | 2.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.64 | $3.99 |
| 52 Week High | $11.68 | $9.99 |
Technical Indicators
Market Signals| Indicator | NTRB | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 47.22 |
| Support Level | N/A | $3.99 |
| Resistance Level | $4.50 | $6.39 |
| Average True Range (ATR) | 0.22 | 0.42 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 33.72 | 61.65 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.